HOME
SEARCH
RSS FEED
SUBSCRIBE
Recombinant Nucleic-Acid Based Flavivirus Nucleic Acids for Development of Vaccines and/or Sero-diagnostics
Case ID:
TAB-2747
Web Published:
12/6/2022
Description:
CDC scientists have developed recombinant flavivirus nucleic acids for the generation of broad protective immunity against flaviviruses, as well as the development of sensitive serologic diagnostic tools. Mosquito borne viral encephalitis is often caused by a flavivirus, such as Japanese encephalitis virus, dengue virus or West Nile virus. Infection by these pathogens is often lethal to both humans and animals.
Specifically, these novel recombinant nucleic acids encode critical structural proteins of flaviviruses, such as yellow fever virus. The invention provides for a method of immunizing a subject against infection by a number of pathogenic flaviviruses. Furthermore, generated antigenic subviral particles can also serve as a tool for the development of specific, antibody detection-based flavivirus diagnostic assays.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech?title=Recombinant_Nucleic-Acid_Based _Flavivirus_Nucleic_Acids_for_Development_of_Vaccines_and%2for_Sero-diagnostics
Category(s):
Licensing
Diagnostics
Vaccines
Therapeutics
Research Materials
Consumer Products
Infectious Disease
Research Equipment
Bookmark this page
Download as PDF
For Information, Contact:
Jeremiah Mitzelfelt
NIH Technology Transfer
301-443-8518
jeremiah.mitzelfelt@nih.gov
Inventors:
Gwong-Jen Chang
Keywords:
Acid
CDC Docket Import
CDC Docket Import CDC Prosecuting
DA4BXX
DA4XXX
DAXXXX
DC1XXX
DC5BXX
DC5XXX
DCXXXX
DXXXXX
Flavivirus
Infection
Nucleic
OID-NCEZID-DVBD
Prevention
vaccines
VLXXXX
VOXXXX
WBXXXX
WDXXXX
WIXXXX
WMXXXX
XEXXXX
XHXXXX
YBXXXX
YCXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum